Faropenem medoxomil

法罗培南酯

Report date: 2023/04/25 13:51:14
NME

Base Information

Drug NameFaropenem medoxomil
Drug Alias NameFaropenem daloxate (Rec INNM)Faropenem medoxomil (USAN)OrapemBAY-56-6854SUN-208 +[7] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionBacterial beta-lactamase TEM inhibitorsCell wall inhibitors
TargetsBacterial beta-lactamase TEMBacterial penicillin-binding protein
Therapy Area/IndicationsOtitis MediaBronchitis, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesCosta RicaIsrael
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesReplidyne Inc
Active IndicationsN/A
Inactive IndicationsOtitis MediaBronchitis, Chronic

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG